Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid-Free Immunosuppression in Pediatric Renal Transplantation
NCT00141037Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2004
- Primary completion
- Sep 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daclizumab in kidney transplantation (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Difference in Linear Growth by Treatment Assignment at 1 year and Number of Biopsy-Proven Acute Rejections at 12 months. Started Mar 2004; status: completed.
02
Drugs
daclizumab
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT00141037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141037.